CN Patent

CN103508961B — 抗肿瘤药物

Assigned to Zhejiang Guanke Meibo Biotechnology Co Ltd · Expires 2015-07-22 · 11y expired

What this patent protects

本发明涉及式I的化合物及其药用盐，其中M，L，A，W，X，Y，Z，和R 1 至R 4 如说明书中所定义。本发明还涉及含有这些化合物的药物组合物，它们的制备方法和它们在制备用于治疗癌症的药物的应用。式I 。

USPTO Abstract

本发明涉及式I的化合物及其药用盐，其中M，L，A，W，X，Y，Z，和R 1 至R 4 如说明书中所定义。本发明还涉及含有这些化合物的药物组合物，它们的制备方法和它们在制备用于治疗癌症的药物的应用。式I 。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN103508961B
Jurisdiction: CN
Classification: —
Expires: 2015-07-22
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang Guanke Meibo Biotechnology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.